Alpha Cognition’s ALPHA-1062 Becomes the Second Oral FDA-Approved Treatment for Alzheimer’s Disease

August 1, 2024

Bausch + Lomb Ends BL1107 Glaucoma Program After Phase 2 Trial Misses Main Goal

July 11, 2026

How Is AI Transforming Market Access and Commercial Decision-Making?

April 14, 2026

Must Read

Theramex purchases Asieris’ innovative cervical lesion treatment for up to $250 million

October 10, 2026

MimiVax’s brain cancer vaccine misses phase 2b goal, but CEO sees a path forward in younger patients

October 10, 2026

Cerevance’s Solengepras Meets Phase 3 Goal in Parkinson’s Disease Trial

October 10, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Novo Launches Late-Stage Trial of Lower-Dose Wegovy Pill for Weight Management

Oregon Study Finds Triple-Drug Regimen Kept Infant Macaques HIV-Free for One Year

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

MimiVax’s brain cancer vaccine misses phase 2b goal, but CEO sees a path forward in younger patients

Cerevance’s Solengepras Meets Phase 3 Goal in Parkinson’s Disease Trial

Zealand’s obesity medication fails once more in phase 3

Phase 3 Firmonertinib Study Misses Primary Endpoint in EGFR Exon 20 NSCLC

Theramex purchases Asieris’ innovative cervical lesion treatment for up to $250 million

Novartis agrees to pay Abogen $7.8 billion for its in vivo autoimmune T-cell engager

Merck anticipates a significant win for the $3 billion eye disease opportunity

Suki Launches AI Dictation Tool Integrated With Epic and Meditech EHRs

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

How Healthcare Organizations Are Building AI Centers of Excellence

The Rise of Platform Biotech Companies

Top 10 Emerging Modalities Beyond RNA Therapeutics

Top 10 ESG Priorities for Life Sciences Companies

Tag: SurVaxM

MimiVax’s brain cancer vaccine misses phase 2b goal, but CEO sees a path forward in younger patients

Editor Picks

Alpha Cognition’s ALPHA-1062 Becomes the Second Oral FDA-Approved Treatment for Alzheimer’s Disease

Bausch + Lomb Ends BL1107 Glaucoma Program After Phase 2 Trial Misses Main Goal

How Is AI Transforming Market Access and Commercial Decision-Making?

Must Read

Theramex purchases Asieris’ innovative cervical lesion treatment for up to $250 million

MimiVax’s brain cancer vaccine misses phase 2b goal, but CEO sees a path forward in younger patients

Cerevance’s Solengepras Meets Phase 3 Goal in Parkinson’s Disease Trial

Hot Topics

About Us

Follow Us